|
| 36224377 | Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry. | Prostate Cancer Prostatic Dis | 2023 |
| 37568624 | Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence. | Cancers (Basel) | 2023 |
| 35804188 | Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. | Prostate Cancer Prostatic Dis | 2023 |
| 37458966 | Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide. | Clin Pharmacokinet | 2023 |
| 37124522 | A comparison of machine learning models for predicting urinary incontinence in men with localized prostate cancer. | Front Oncol | 2023 |
| 37117107 | Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review. | Eur Urol | 2023 |
| 37345149 | Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37164814 | Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC. | Clin Genitourin Cancer | 2023 |
| 36996325 | Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 36874601 | Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting. | Eur Urol Open Sci | 2023 |
| 36867616 | Development and external validation of multivariate prediction models for erectile dysfunction in men with localized prostate cancer. | PLoS One | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34253846 | Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 35840723 | Editor' summary: A paradigm shift in castration-resistant prostate cancer management. | Prostate Cancer Prostatic Dis | 2022 |
| 35800157 | Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. | Oncoimmunology | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35654644 | Corrigendum to "Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study". | Urol Oncol | 2022 |
| 36581909 | Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study. | BMC Cancer | 2022 |
| 36612293 | PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study. | Cancers (Basel) | 2022 |
| 36124924 | Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. | Oncologist | 2022 |
| 36010883 | Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review. | Cancers (Basel) | 2022 |
| 35314962 | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. | Drugs Real World Outcomes | 2022 |
| 34912074 | Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. | Br J Cancer | 2022 |
| 35210590 | Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. | Br J Cancer | 2022 |
| 35205807 | The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review. | Cancers (Basel) | 2022 |
| 34436788 | The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. | Br J Clin Pharmacol | 2022 |
| 34599663 | Adjustment disorder in cancer patients after treatment: prevalence and acceptance of psychological treatment. | Support Care Cancer | 2022 |
| 34774465 | Dissemination of the European Association of Urology Guidelines Through Social Media: Strategy, Results, and Future Developments. | Eur Urol Focus | 2022 |
| 34848157 | Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. | Clin Genitourin Cancer | 2022 |
| 34358388 | Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer. | BJU Int | 2022 |
| 31601523 | Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. | Eur Urol Oncol | 2021 |
| 33883176 | Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. | Clin Cancer Res | 2021 |
| 33686456 | Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. | Eur J Nucl Med Mol Imaging | 2021 |
| 33650292 | Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. | Mol Oncol | 2021 |
| 33746212 | The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. | Prostate Cancer Prostatic Dis | 2021 |
| 34944897 | RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2021 |
| 34900722 | Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study. | Front Oncol | 2021 |
| 34736509 | Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. | Trials | 2021 |
| 34388386 | Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. | Lancet Oncol | 2021 |
| 34415798 | High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. | J Palliat Med | 2021 |
| 33941866 | Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. | Prostate Cancer Prostatic Dis | 2021 |
| 34092439 | A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. | Eur Urol | 2021 |
| 34315625 | Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. | Eur Urol | 2021 |
| 31748122 | Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study. | Eur Urol Focus | 2021 |
| 33172773 | A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines. | Eur Urol Focus | 2021 |
| 33353867 | Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with <sup>225</sup>Ac-PSMA-617 targeted alpha-radiation therapy. | Urol Oncol | 2021 |
| 32999466 | Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. | Prostate Cancer Prostatic Dis | 2021 |
| 32965028 | Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. | Int J Cancer | 2021 |